Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding.
about
Digested disorder: Quarterly intrinsic disorder digest (January/February/March, 2013).The AFF4 scaffold binds human P-TEFb adjacent to HIV TatDegree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.Importance of a specific amino acid pairing for murine MLL leukemias driven by MLLT1/3 or AFF1/4Conditionally disordered proteins: bringing the environment back into the fold.The molecular mechanics of mixed lineage leukemia.The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV.Identification of hidden relationships from the coupling of hydrophobic cluster analysis and domain architecture information.Development of a high-throughput screening-compatible assay for the discovery of inhibitors of the AF4-AF9 interaction using AlphaScreen technologyComprehensive repertoire of foldable regions within whole genomes.Binding cavities and druggability of intrinsically disordered proteins.Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?A meta-analysis reveals complex regulatory properties at Taf14-repressed genes.MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.CBX8, a component of the Polycomb PRC1 complex, modulates DOT1L-mediated gene expression through AF9/MLLT3An AF9/ENL-targted peptide with therapeutic potential in mixed lineage leukemias.Structural basis for ELL2 and AFF4 activation of HIV-1 proviral transcriptionDeep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.Physical and functional interaction of Rnf2 with Af9 regulates basal and aldosterone-stimulated transcription of the α-ENaC gene in a renal collecting duct cell line.The Bucentaur (BCNT) protein family: a long-neglected class of essential proteins required for chromatin/chromosome organization and function.The upstreams and downstreams of H3K79 methylation by DOT1L.Collaboration of MLLT1/ENL, Polycomb and ATM for transcription and genome integrity.MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.TBP loading by AF4 through SL1 is the major rate-limiting step in MLL fusion-dependent transcription.Building a super elongation complex for HIV.Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells.DOT1L and H3K79 Methylation in Transcription and Genomic Stability.The RING Domain of the Scaffold Protein Ste5 Adopts a Molten Globular Character with High Thermal and Chemical Stability
P2860
Q22061724-528B652D-288E-4EAA-A4BD-4D3D05D339E6Q27676733-2A7EBA45-7DCF-453E-AE40-C7071548EDE0Q30300029-18032D84-4169-4C8A-B4CB-143D17F59506Q30303155-8747C387-1811-4F67-BDF5-DA93674E947EQ30402882-B0294C52-B7CC-4684-8C02-907A055189DFQ34516051-25991478-D42F-4E56-B77E-102E1E1477D0Q34683981-DB5E9F7B-B100-4AAC-822A-628C51C10C01Q34725052-67A7CA3D-308B-4ADB-919D-C9B0D670B4FBQ34726135-50284E13-18EB-4201-A78D-397B6A4895D6Q35034116-5DE0E841-9E16-439E-B3F7-EFE185D97B47Q35571730-E28092FB-A7A2-4A12-AF38-0456559269D0Q35687836-C45E1427-2926-4C70-881F-F092C22A50D5Q36283300-54959646-A0BA-465E-B117-1C69462C146BQ36426910-13448AE5-ED42-451B-B7A3-F42FE6710FFBQ37234107-040634AF-F08E-481E-850E-99DCF60F9F9CQ37238213-312D0C88-6B3C-473C-AC6C-2E9DDE82A885Q37519680-E5884308-BECF-412E-B50D-7D44A9BEC7E4Q37622516-FB084184-4EA7-455F-9E90-C6C9D155C69CQ37665574-9C4BBD34-E68D-4809-8A58-F586C57C3B4BQ37691342-B28744F6-A6ED-49A6-A0C9-21452CB78137Q38303149-6639DB2F-78DB-41C1-B2F5-648C37BF4125Q38686217-7164EC2B-BEB8-4E97-9DDF-6077A4B54C07Q38867022-1B7CB540-8BEF-4C02-A879-C1866A376116Q39004166-78E8545A-6070-4287-9EC7-01D9AB5751D0Q41352951-AF511C99-88EC-4506-A3AA-39373E42175DQ41440692-AD3A9B1D-916F-48AA-BB14-1FA5373F7676Q42260284-D22298C9-D074-431A-B12A-357DB8ED0963Q42773788-E7840CCF-4BED-4A23-BB5D-514C6DFBF105Q52729540-93ADFAE1-9F4B-45D4-AFCC-E2E928F09101Q57825646-83203D46-F0C8-4B39-8D92-27874C47760D
P2860
Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Leukemia Fusion Target AF9 Is ...... ia Coupled Folding and Binding
@nl
Leukemia fusion target AF9 is ...... a coupled folding and binding.
@ast
Leukemia fusion target AF9 is ...... a coupled folding and binding.
@en
type
label
Leukemia Fusion Target AF9 Is ...... ia Coupled Folding and Binding
@nl
Leukemia fusion target AF9 is ...... a coupled folding and binding.
@ast
Leukemia fusion target AF9 is ...... a coupled folding and binding.
@en
prefLabel
Leukemia Fusion Target AF9 Is ...... ia Coupled Folding and Binding
@nl
Leukemia fusion target AF9 is ...... a coupled folding and binding.
@ast
Leukemia fusion target AF9 is ...... a coupled folding and binding.
@en
P2093
P2860
P1433
P1476
Leukemia fusion target AF9 is ...... ia coupled folding and binding
@en
P2093
Aravinda Kuntimaddi
Charles R Schmidt
Stephanie A Johnson
Tomasz Cierpicki
P2860
P304
P356
10.1016/J.STR.2012.11.011
P577
2012-12-20T00:00:00Z